It has been reported that treatment with trichostatin A (TSA), a I/II HDAC inhibitor, significantly attenuated renal damage and improved renal function in a murine model of cisplatin-induced AKI (Liu et al., 2018); administration of valproic acid, another class I/II HDAC inhibitor, also promoted renal recovery in a murine model of AKI induced by ischemia/reperfusion (Costalonga et al., 2016). This evidence concerns the gene HDAC9 and acute kidney injury.